FDA approved a supplemental biologics license application (sBLA) for Leqembi Iqlik (lecanemab-irmb) as a once-weekly subcutaneous initiation dose for early Alzheimer's disease.

The approval provides both patients and caregivers the first at-home administration option available throughout the Alzheimer's treatment journey, and comes after the agency’s previous request to extend the priority review process.

Leqembi is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease — the earliest symptomatic stages of the disease, which can present as forgetfulness, confusion or difficulty finding words.

What is the treatment process?

The initiation regimen consists of 500 mg given once weekly as two 250 mg injections delivered via autoinjector, each completed in approximately 15 seconds.¹ After 18 months of either intravenous (IV) or subcutaneous treatment, patients may switch to a maintenance dose of 360 mg once weekly.

Patients also retain the flexibility to alternate between IV infusion and subcutaneous administration throughout their treatment course. Leqembi Iqlik for initiation dosing is expected to be available in the U.S. in late August 2026 through specialty pharmacy.¹

What is the approval based on?

The approval was supported by sub-studies within the Phase III Clarity AD long-term extension, which followed the 18-month core study in patients with early Alzheimer's disease.² Sub-studies showed that once-weekly subcutaneous administration achieved exposure equivalent to intravenous dosing, supporting similar efficacy and amyloid removal benefits. The rate of exposure-related adverse events, including Aria-E, was expected to be comparable between subcutaneous and IV administration, along with no increase in isolated ARIA-H with Leqembi compared to placebo.²The overall safety profile of subcutaneous administration was generally similar to IV, with injection-related reactions that were mostly localized; systemic reactions were less frequently observed.

In a separate autoinjector acceptability study, 94% of patients with early Alzheimer's disease and their care partners found the Leqembi Iqlik device easy to use, with high levels of satisfaction and confidence in using it at home.¹

Why does this matter for patients?

The approval of Leqembi Iqlik has the potential to reduce the frequency of clinic visits, lower reliance on infusion infrastructure, decrease treatment preparation and administration time, and preserve infusion capacity for patients who prefer or require IV therapy.

"The approval of Leqembi Iqlik for initiation dosing marks a new era of Alzheimer's treatments," said Howard Fillit, co-founder and chief science officer emeritus of the Alzheimer's Drug Discovery Foundation. "For the first time, patients and their care partners have meaningful choice in how anti-amyloid treatment is delivered. As treatment approaches continue to expand, innovations in drug delivery will play a critical role in improving access to therapies, supporting the investigation of potential combination treatments, and advancing a precision medicine approach to Alzheimer's care."

What support is available for patients?

Alongside FDA’s approval, Eisai and Biogen have established the Leqembi Companion program to assist with insurance coverage questions, out-of-pocket cost estimates and financial support programs, including a copay assistance program for eligible patients.¹ Eisai's Patient Assistance Program will also provide both Leqembi and Leqembi Iqlik at no cost to eligible uninsured patients who meet financial need and other program criteria.

Eisai serves as the lead for lecanemab's development and regulatory submissions globally and holds final decision-making authority, with Biogen co-commercializing and co-promoting the product.

Sources

1. FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease Biogen July 13, 2026 https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembi-iqlikr-lecanemab-irmb-subcutaneous
2. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study National Library of Medicine December 21, 2025 https://pubmed.ncbi.nlm.nih.gov/41355080/